Top Markets
#1 ADO Protocol ADO Protocol +194.72%
#2 Islamic Coin Islamic Coin +155.37%
#3 GoPlus Security GoPlus Security +40.11%
#4 GAIB AID GAIB AID +24.67%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.15%
#6 TENDIES TENDIES +16.67%
#7 Wrapped NXM Wrapped NXM +14.87%
#8 Verus Coin Verus Coin +13.64%
#9 Tutorial Tutorial +13.32%
#10 Pons Pons +12.61%
Coin of the day
ADO Protocol ADO Protocol
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Apimeds Pharmaceuticals US, Inc Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc

APUS
Kedudukan dalam Saham #33693
Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage... Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.
Harga Saham
$4.70
Disegerakkan terakhir: 2026-08-14
Modal Pasaran
$7.09M
Perubahan (1 hari)
-0.21%
Perubahan (1 tahun)
-70.63%
Negara
US
Perdagangan Apimeds Pharmaceuticals US, Inc (APUS)

Kategori

Healthcare
Hasil untuk Apimeds Pharmaceuticals US, Inc (APUS)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada Apimeds Pharmaceuticals US, Inc, hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Apimeds Pharmaceuticals US, Inc dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE